Zoetis Inc. (ZTS) EV/EBITDA Ratio: 10.33x
Is Zoetis Inc.’s EV/EBITDA ratio high or low?
Zoetis Inc.'s EV/EBITDA ratio of 10.33x is 57% below its 5-year average of 23.76x, near the low end of its 5-year range (9.57x–39.29x).
The EV/EBITDA ratio for Zoetis Inc. (ZTS) is 10.33x as of Wednesday, June 10, 2026. It is below its 12-month average by 34.10% (15.67x).
ZTS EV/EBITDA Ratio Chart
ZTS Average EV/EBITDA Ratio Chart
ZTS Current vs Average EV/EBITDA Ratio Chart
ZTS EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
10.33x
EV/EBITDA RATIO AVG TTM
15.67x
EV/EBITDA RATIO AVG 3Y
20.68x
EV/EBITDA RATIO AVG 5Y
23.76x
EV/EBITDA RATIO AVG 10Y
24.26x
EV/EBITDA RATIO AVG 15Y
23.37x
EV/EBITDA RATIO AVG 20Y
23.37x
CURRENT VS TTM AVG
-34.10%
CURRENT VS 3Y AVG
-50.06%
CURRENT VS 5Y AVG
-56.53%
CURRENT VS 10Y AVG
-57.41%
CURRENT VS 15Y AVG
-55.80%
CURRENT VS 20Y AVG
-55.80%
ZTS Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | — | 10.33x | 15.67x | 20.68x | 23.76x |
| Centene Corporation (CNC) | $31.94B | N/A | 4.99x | 7.28x | 9.49x |
| Agilent Technologies, Inc. (A) | $37.17B | 20.92x | 21.12x | 21.69x | 23.11x |
| IQVIA Holdings Inc. (IQV) | $30.60B | 8.90x | 13.19x | 14.98x | 17.09x |
| DexCom, Inc. (DXCM) | $29.24B | 23.24x | 28.10x | 43.48x | 70.03x |
| Biogen Inc. (BIIB) | $29.00B | 11.60x | 8.56x | 11.16x | 12.22x |
| Veeva Systems Inc. (VEEV) | $27.37B | 26.02x | 43.41x | 56.96x | 62.43x |
| Humana Inc. (HUM) | $43.78B | 18.61x | 11.68x | 11.33x | 12.36x |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 30.48x | 35.75x | 34.46x | 38.26x |
| Waters Corporation (WAT) | $23.83B | 38.03x | 21.59x | 21.24x | 21.45x |
EV/EBITDA vs. its own history
At 10.3, EV/EBITDA is cheaper than usual — richer than 1% of its 13-year range.
13-year low
9.6
median
22.7
13-year high
39.3
Understanding EV/EBITDA
Enterprise Value (EV) = Market Cap + Total Debt - Cash
EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization
EV/EBITDA is commonly used for comparing companies because:
- It accounts for debt levels (capital structure neutral)
- It removes effects of different depreciation policies
- It can be compared across countries with different tax rates
- It can remain available when net income is negative, if EBITDA is positive
Zoetis Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Zoetis Inc. (ZTS)?
- The EV/EBITDA ratio for ZTS stock is 10.33x.
- Is Zoetis Inc.'s EV/EBITDA ratio high or low?
- Zoetis Inc.'s EV/EBITDA ratio of 10.33x is 57% below its 5-year average of 23.76x, near the low end of its 5-year range (9.57x–39.29x).
- What is the TTM average EV/EBITDA ratio for Zoetis Inc. (ZTS)?
- The TTM average EV/EBITDA ratio for ZTS stock is 15.67x.
- What is the 3Y average EV/EBITDA ratio for Zoetis Inc. (ZTS)?
- The 3Y average EV/EBITDA ratio for ZTS stock is 20.68x.
- What is the 5Y average EV/EBITDA ratio for Zoetis Inc. (ZTS)?
- The 5Y average EV/EBITDA ratio for ZTS stock is 23.76x.
- What is the 10Y average EV/EBITDA ratio for Zoetis Inc. (ZTS)?
- The 10Y average EV/EBITDA ratio for ZTS stock is 24.26x.
- What is the 15Y average EV/EBITDA ratio for Zoetis Inc. (ZTS)?
- The 15Y average EV/EBITDA ratio for ZTS stock is 23.37x.
- What is the 20Y average EV/EBITDA ratio for Zoetis Inc. (ZTS)?
- The 20Y average EV/EBITDA ratio for ZTS stock is 23.37x.
Zoetis Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-10 | 10.33x |
| 2026-06-09 | 10.40x |
| 2026-06-08 | 10.05x |
| 2026-06-05 | 10.11x |
| 2026-06-04 | 10.12x |
| 2026-06-03 | 9.92x |
| 2026-06-02 | 9.79x |
| 2026-06-01 | 9.92x |
| 2026-05-29 | 9.93x |
| 2026-05-28 | 9.99x |
| 2026-05-27 | 10.12x |
| 2026-05-26 | 10.19x |
| 2026-05-22 | 10.31x |
| 2026-05-21 | 10.18x |
| 2026-05-20 | 10.14x |
| 2026-05-19 | 10.06x |
| 2026-05-18 | 9.93x |
| 2026-05-15 | 9.57x |
| 2026-05-14 | 9.70x |
| 2026-05-13 | 9.58x |
| 2026-05-12 | 9.85x |
| 2026-05-11 | 9.82x |
| 2026-05-08 | 10.47x |
| 2026-05-07 | 10.94x |
| 2026-05-06 | 13.69x |
| 2026-05-05 | 13.83x |
| 2026-05-04 | 13.85x |
| 2026-05-01 | 14.01x |
| 2026-04-30 | 14.10x |
| 2026-04-29 | 13.97x |
| 2026-04-28 | 14.28x |
| 2026-04-27 | 14.41x |
| 2026-04-24 | 14.30x |
| 2026-04-23 | 14.21x |
| 2026-04-22 | 14.37x |
| 2026-04-21 | 14.44x |
| 2026-04-20 | 14.93x |
| 2026-04-17 | 14.89x |
| 2026-04-16 | 14.53x |
| 2026-04-15 | 14.72x |
| 2026-04-14 | 14.75x |
| 2026-04-13 | 14.64x |
| 2026-04-10 | 14.41x |
| 2026-04-09 | 14.63x |
| 2026-04-08 | 14.61x |
| 2026-04-07 | 14.29x |
| 2026-04-06 | 14.45x |
| 2026-04-02 | 14.41x |
| 2026-04-01 | 14.34x |
| 2026-03-31 | 14.44x |
| 2026-03-30 | 14.24x |
| 2026-03-27 | 13.92x |
| 2026-03-26 | 14.27x |
| 2026-03-25 | 14.28x |
| 2026-03-24 | 14.20x |
| 2026-03-23 | 14.12x |
| 2026-03-20 | 14.17x |
| 2026-03-19 | 14.21x |
| 2026-03-18 | 14.35x |
| 2026-03-17 | 14.82x |
| 2026-03-16 | 14.44x |
| 2026-03-13 | 14.17x |
| 2026-03-12 | 14.15x |
| 2026-03-11 | 14.61x |
| 2026-03-10 | 14.69x |
| 2026-03-09 | 14.89x |
| 2026-03-06 | 14.79x |
| 2026-03-05 | 14.87x |
| 2026-03-04 | 15.28x |
| 2026-03-03 | 15.27x |
| 2026-03-02 | 15.60x |
| 2026-02-27 | 15.83x |
| 2026-02-26 | 15.68x |
| 2026-02-25 | 15.60x |
| 2026-02-24 | 15.56x |
| 2026-02-23 | 15.26x |
| 2026-02-20 | 15.58x |
| 2026-02-19 | 15.42x |
| 2026-02-18 | 15.62x |
| 2026-02-17 | 15.23x |
| 2026-02-13 | 15.35x |
| 2026-02-12 | 15.24x |
| 2026-02-11 | 15.36x |
| 2026-02-10 | 15.30x |
| 2026-02-09 | 15.21x |
| 2026-02-06 | 15.22x |
| 2026-02-05 | 15.15x |
| 2026-02-04 | 15.14x |
| 2026-02-03 | 14.67x |
| 2026-02-02 | 14.95x |
| 2026-01-30 | 14.94x |
| 2026-01-29 | 14.60x |
| 2026-01-28 | 14.62x |
| 2026-01-27 | 14.95x |
| 2026-01-26 | 14.84x |
| 2026-01-23 | 14.85x |
| 2026-01-22 | 14.89x |
| 2026-01-21 | 14.97x |
| 2026-01-20 | 14.76x |
| 2026-01-16 | 14.92x |
| 2026-01-15 | 14.99x |
| 2026-01-14 | 15.05x |
| 2026-01-13 | 14.91x |
| 2026-01-12 | 14.99x |
| 2026-01-09 | 15.19x |
| 2026-01-08 | 15.16x |
| 2026-01-07 | 15.03x |
| 2026-01-06 | 15.43x |
| 2026-01-05 | 15.43x |
| 2026-01-02 | 15.06x |
| 2025-12-31 | 15.05x |
| 2025-12-30 | 15.11x |
| 2025-12-29 | 15.06x |
| 2025-12-26 | 15.09x |
| 2025-12-24 | 15.01x |
| 2025-12-23 | 14.80x |
| 2025-12-22 | 14.82x |
| 2025-12-19 | 14.65x |
| 2025-12-18 | 14.71x |
| 2025-12-17 | 14.66x |
| 2025-12-16 | 14.76x |
| 2025-12-15 | 14.52x |
| 2025-12-12 | 14.26x |
| 2025-12-11 | 14.15x |
| 2025-12-10 | 14.20x |
| 2025-12-09 | 13.94x |
| 2025-12-08 | 14.21x |
| 2025-12-05 | 14.26x |
| 2025-12-04 | 14.45x |
| 2025-12-03 | 14.69x |
| 2025-12-02 | 14.90x |
| 2025-12-01 | 15.20x |
| 2025-11-28 | 15.30x |
| 2025-11-26 | 15.25x |
| 2025-11-25 | 15.27x |
| 2025-11-24 | 14.72x |
| 2025-11-21 | 14.63x |
| 2025-11-20 | 13.96x |
| 2025-11-19 | 14.09x |
| 2025-11-18 | 14.21x |
| 2025-11-17 | 14.28x |
| 2025-11-14 | 14.50x |
| 2025-11-13 | 14.54x |
| 2025-11-12 | 14.55x |
| 2025-11-11 | 14.42x |
| 2025-11-10 | 14.39x |
| 2025-11-07 | 14.44x |
| 2025-11-06 | 14.36x |
| 2025-11-05 | 14.46x |
| 2025-11-04 | 14.90x |
| 2025-11-03 | 17.25x |
| 2025-10-31 | 17.22x |
| 2025-10-30 | 17.22x |
| 2025-10-29 | 17.21x |
| 2025-10-28 | 17.37x |
| 2025-10-27 | 17.60x |
| 2025-10-24 | 17.43x |
| 2025-10-23 | 17.48x |
| 2025-10-22 | 17.56x |
| 2025-10-21 | 17.44x |
| 2025-10-20 | 17.33x |
| 2025-10-17 | 17.22x |
| 2025-10-16 | 17.13x |
| 2025-10-15 | 17.01x |
| 2025-10-14 | 17.15x |
| 2025-10-13 | 17.02x |
| 2025-10-10 | 16.89x |
| 2025-10-09 | 17.15x |
| 2025-10-08 | 17.16x |
| 2025-10-07 | 17.08x |
| 2025-10-06 | 17.36x |
| 2025-10-03 | 17.48x |
| 2025-10-02 | 17.49x |
| 2025-10-01 | 17.54x |
| 2025-09-30 | 17.47x |
| 2025-09-29 | 17.11x |
| 2025-09-26 | 17.16x |
| 2025-09-25 | 16.90x |
| 2025-09-24 | 16.96x |
| 2025-09-23 | 17.06x |
| 2025-09-22 | 17.29x |
| 2025-09-19 | 17.42x |
| 2025-09-18 | 17.56x |
| 2025-09-17 | 17.54x |
| 2025-09-16 | 17.60x |
| 2025-09-15 | 17.46x |
| 2025-09-12 | 17.68x |
| 2025-09-11 | 17.94x |
| 2025-09-10 | 17.81x |
| 2025-09-09 | 17.85x |
| 2025-09-08 | 18.07x |
| 2025-09-05 | 18.24x |
| 2025-09-04 | 18.23x |
| 2025-09-03 | 18.14x |
| 2025-09-02 | 18.19x |
| 2025-08-29 | 18.58x |
| 2025-08-28 | 18.40x |
| 2025-08-27 | 18.47x |
| 2025-08-26 | 18.40x |
| 2025-08-25 | 18.45x |
| 2025-08-22 | 18.61x |
| 2025-08-21 | 18.49x |
| 2025-08-20 | 18.62x |
| 2025-08-19 | 18.50x |
| 2025-08-18 | 18.13x |
| 2025-08-15 | 18.33x |
| 2025-08-14 | 18.21x |
| 2025-08-13 | 18.14x |
| 2025-08-12 | 17.85x |
| 2025-08-11 | 17.77x |
| 2025-08-08 | 17.58x |
| 2025-08-07 | 17.68x |
| 2025-08-06 | 17.49x |
| 2025-08-05 | 17.45x |
| 2025-08-04 | 18.61x |
| 2025-08-01 | 18.10x |
| 2025-07-31 | 17.92x |
| 2025-07-30 | 18.27x |
| 2025-07-29 | 18.52x |
| 2025-07-28 | 18.49x |
| 2025-07-25 | 18.64x |
| 2025-07-24 | 18.72x |
| 2025-07-23 | 18.80x |
| 2025-07-22 | 18.54x |
| 2025-07-21 | 18.10x |
| 2025-07-18 | 18.24x |
| 2025-07-17 | 18.41x |
| 2025-07-16 | 18.58x |
| 2025-07-15 | 18.73x |
| 2025-07-14 | 19.05x |
| 2025-07-11 | 18.97x |
| 2025-07-10 | 19.41x |
| 2025-07-09 | 19.35x |
| 2025-07-08 | 19.29x |
| 2025-07-07 | 19.21x |
| 2025-07-03 | 19.45x |
| 2025-07-02 | 19.44x |
| 2025-07-01 | 19.45x |
| 2025-06-30 | 19.08x |
| 2025-06-27 | 19.11x |
| 2025-06-26 | 19.06x |
| 2025-06-25 | 19.23x |
| 2025-06-24 | 19.29x |
| 2025-06-23 | 19.24x |
| 2025-06-20 | 19.22x |
| 2025-06-18 | 18.98x |
| 2025-06-17 | 19.73x |
| 2025-06-16 | 20.04x |
| 2025-06-13 | 20.04x |
| 2025-06-12 | 20.55x |
| 2025-06-11 | 20.27x |
| 2025-06-10 | 20.35x |
| 2025-06-09 | 20.07x |
| 2025-06-06 | 20.70x |
| 2025-06-05 | 20.53x |
| 2025-06-04 | 20.52x |
| 2025-06-03 | 20.72x |
| 2025-06-02 | 20.62x |
| 2025-05-30 | 20.53x |
| 2025-05-29 | 20.36x |
Showing the most recent 260 of 3,359 data points. The chart above shows the full history.
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck